MarketLens
Sign Up

Has Hims & Hers' GLP-1 Gamble Backfired Permanently

7 months ago
SHARE THIS ON:

Has Hims & Hers' GLP-1 Gamble Backfired Permanently

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

Hims & Hers Health's Next Act: Making Its Own Drugs Again

Hims & Hers Health's 2Q revenue rose 38% to $753.2M, and FY outlook was raised to $3.1–$3.3B, after branded GLP-1 distribution drove growth. Gross margin fell 6 points sequentially to 64%, pressuring ...
Stock News•2 months ago

Is Hims & Hers Health Stock in Trouble?

Hims & Hers Health stock fell more than 50% over the past 12 months, reflecting a sharp decline in investor confidence amid ongoing market pressures.
Stock News•2 months ago

Market Matters Ep. 12: How HIMS Could Benefit From FDA Changes

Hims & Hers could gain from the FDA's impending peptide regulation decision, per DocShah Financial CEO Raul Shah. The analysis also covers UnitedHealth's outlook and broader health care sector implica...

Breaking News

View All →

No topics available at the moment

Top Headlines

View More →
Stock News•54 minutes ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•1 hour ago

Why the Market Dipped But Meta Platforms (META) Gained Today

Stock News•1 hour ago

Nvidia in 5 Years: Where the Stock Could Be Headed

Stock News•2 hours ago

UK finance minister Healey to target online marketplaces in tax crackdown, The Times reports

Stock News•2 hours ago

Character.AI owes Google and Big Law firms nearly $7M, court filings show